Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status:
Terminated
Trial end date:
2019-08-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of
rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced
solid tumors.